Nivolumab,Ipilimumab
BMS
[]
part b will be very important but lower power as initially to support efficacy of components of parts for the doublet. #esmo2022 
GU medical oncologist @UCSanDiego, mom, wife, avid runner. Kidney and prostate cancer research. Tweets are my own and not medical advice.